PGE-M

• Description:

  PGE-M is a metabolite of prostaglandin E2 (PEG2) as a biomarker of inflammation and cancer including advanced colorectal neoplasia, ovarian cancer, prostate cancer and so on. Urinary PGE-M is positively associated with obesity, smoking and lung metastases with breast cancer[1][2][3].

• Product Name Alternative:

  Tetranor-PGEM

• UNSPSC:

  12352211

• Hazard Statement:

  H225, H319, H336

• Target:

  Endogenous Metabolite

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/pge-m.html

• Concentration:

  304.54 μM * 250 μL in Methyl acetate

• Purity:

  99.9

• Solubility:

  10 mM in DMSO

• Smiles:

  O[C@H]1[C@@H]([C@H](C(C1)=O)CCC(O)=O)CCC(CCCCC(O)=O)=O

• Molecular Formula:

  C16H24O7

• Molecular Weight:

  328.36

• Precautions:

  H225, H319, H336

• References & Citations:

  [1]Johnson JC, et al. Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin Gastroenterol Hepatol. 2006 Nov;4 (11) :1358-65.|[2]Wang D, DuBois RN. Urinary PGE-M: a promising cancer biomarker. Cancer Prev Res (Phila) . 2013 Jun;6 (6) :507-10.|[3]Morris PG, et al. Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer Prev Res (Phila) . 2013 May;6 (5) :428-36.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  -80°C

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [24769-56-0]